UnitedHealthcare gives Remicade biosims a leg up with changes to Medicare plans

UnitedHealthcare
UnitedHealthcare introduced a plan to favor biosimilars over certain brands for Medicare Advantage plans starting next year. (UnitedHealth Group)

Armed with new rules from CMS, UnitedHealthcare is making some moves in its Medicare plans that could hit Johnson & Johnson's Remicade and jump-start biosims from Pfizer, Merck & Co. and more.

The insurance behemoth will roll out step therapy to control costs on pricey biologics, including Remicade, which has managed to hang on to market share despite the multiple biosims now on the market. Anemia drugs Procrit from J&J and Aranesp from Amgen will also face the new barriers.

Which drugs could reap the benefits? Pfizer’s Inflectra and Merck’s Renflexis—both Remicade biosims—are now preferred on Medicare Advantage plans, UnitedHealthcare said in a bulletin. Pfizer’s Retacrit, a biosimilar to Procrit and Amgen’s Epogen, is preferred in the erythropoiesis stimulating-drug category.

Webinar This Week

OTC Innovation to Avoid Stagnation: Survey Insights, Expert Advice, and Latest Technologies to Boost Your Product’s Performance

Join us for a complimentary webinar on November 13 at 11am ET / 8am PT. Listen to industry experts as they analyze the critical role of innovation in OTC products, and strategies for achieving it.

Step therapy—which requires patients to try the preferred drug first—won't apply to Amgen’s Epogen or Roche's Mircera, according to the document, and it won't apply to patients already taking the drugs, either.

RELATED: CMS allows Medicare Advantage plans to negotiate Part B drug prices, implement step therapy

As part of the Trump Administration's plan to control drug costs, the Centers for Medicare & Medicaid Services said in August that it would allow Medicare Advantage plans to negotiate drug prices and use step therapy to help control pharma spending. UnitedHealthcare celebrated the decision at the time, while the American Medical Association said it could cause “unnecessary red tape” and coverage rejections.  

UnitedHealthcare's decision could boost the U.S. biosimilars market, which has so far been slow to take off for a variety of reasons, including drug contracting with payers. Despite the fact that it’s facing two biosimilars, Remicade has retained much of its market share. Pfizer argues in a lawsuit that J&J’s contracting strategy to protect the drug is “anticompetitive.” 

RELATED: UnitedHealthcare and AMA clash over Medicare's step therapy changes 

UnitedHealthcare’s Medicare Advantage changes come about two months after Express Scripts released its formulary for 2019, kicking off 48 drugs. The list included 11 specialty drugs facing cheaper branded rivals or biosimilars. 

Suggested Articles

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.